Advertisement
Singapore markets closed

  • Straits Times Index

    3,287.75
    -5.38 (-0.16%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • Dow

    38,460.92
    -42.77 (-0.11%)
     

  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     

  • Bitcoin USD

    63,429.57
    -3,005.92 (-4.52%)
     

  • CMC Crypto 200

    1,359.16
    -23.41 (-1.69%)
     

  • FTSE 100

    8,075.58
    +35.20 (+0.44%)
     

  • Gold

    2,342.20
    +3.80 (+0.16%)
     

  • Crude Oil

    82.80
    -0.01 (-0.01%)
     

  • 10-Yr Bond

    4.6890
    +0.0370 (+0.80%)
     

  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • FTSE Bursa Malaysia

    1,569.25
    -2.23 (-0.14%)
     

  • Jakarta Composite Index

    7,155.29
    -19.24 (-0.27%)
     

  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Moving Average Crossover Alert: ANI Pharmaceuticals (ANIP)

Zacks Equity Research
Updated

ANI Pharmaceuticals, Inc. ANIP could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for ANIP broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.   

This has already started to take place, as the stock has moved lower by 23% in the past four weeks. And with the recent moving average crossover, investors have to think that more unfavorable trading is ahead for ANIP stock.  

If that wasn’t enough, ANI Pharmaceuticals, Inc. isn’t looking too great from an earnings estimate revision perspective either. It appears as though many analysts have been reducing their earnings expectations for the stock lately, which is usually not a good sign of things to come.

Consider that in the last 30 days, 2 estimates have been reduced, while none has moved higher. Add this in to a similar move lower in the consensus estimate, and there is plenty of reason to be bearish here.

ADVERTISEMENT

That is why we currently have a Zacks Rank #4 (Sell) on this stock and are looking for it to underperform in the weeks ahead. So either avoid this stock or consider jumping ship until the estimates and technical factors turn around for ANIP. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

5 Trades Could Profit "Big-League" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ANI Pharmaceuticals, Inc. (ANIP): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research